PPR

Journey Medical Corporation Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

Retrieved on: 
Monday, May 22, 2023
News, EWB, PPR, Marketing, Clinical trial, NDA, Journey, GAAP, Minocycline, Security, EBITDA, IGA, New Çeltek events, Investment, Research, Adjustment, FDA, Regulation of tobacco by the U.S. Food and Drug Administration, Rosacea, Food, Communications satellite, Pharmaceutical industry, Glycopyrronium tosylate

SCOTTSDALE, Ariz., May 22, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of FDA approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced financial results and recent corporate highlights for the first quarter ended March 31, 2023.

Key Points: 
  • ET
    SCOTTSDALE, Ariz., May 22, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of FDA approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced financial results and recent corporate highlights for the first quarter ended March 31, 2023.
  • In addition, all products were unfavorably impacted by higher gross-to-net adjustments compared to the first quarter of 2022.
  • In January 2023, Journey Medical completed enrollment in its DFD-29 Phase 3 clinical program for the treatment of PPR and achieved the “Last Patient Out” milestone in May 2023.
  • Journey Medical management will conduct a conference call and audio webcast on May 22, 2023, at 4:30 p.m.

Prairie Provident Announces Completion of Recapitalization Transactions and Closing of Fully Subscribed C$4 Million Equity Financing

Retrieved on: 
Tuesday, May 16, 2023
RLI, FOR, Investment, Telephone, Person, Accreditation, Equity, Agent, Acquisition, News, Minority, PPR, Recapitalization, Warrant, Suite, Finance Secretary (India), National instrument, SEDAR, TSX, Multilateral, Disclosure, Equity (finance), Exercise, NOT, NI, Regulation, Indian stock exchange, MI, Sale, Prospectus, Bank, PCEP, Cryptocurrency, Financial services, Security (finance), Insurance, Unit

CALGARY, Alberta, May 16, 2023 (GLOBE NEWSWIRE) -- Prairie Provident Resources Inc. (TSX:PPR) (the “Company”), is pleased to announce the completion of its previously announced recapitalization transactions (collectively, the “Recapitalization”). The Recapitalization included the following principal transactions:

Key Points: 
  • The Company has approximately C$860 million in tax pools (C$560 million of which are available as tax shelter against current income) to complement its reserves value.
  • The Equity Financing was led by Research Capital Corporation as the sole agent and sole bookrunner (the “Agent”).
  • The net proceeds from the Equity Financing will be used for ongoing field operations, working capital requirements and other general corporate purposes.
  • Certain directors and officers of the Company participated in the Equity Financing under applicable securities laws, acquiring 7,424,423 Units in total.

Prairie Provident Resources Announces First Quarter 2023 Financial and Operating Results

Retrieved on: 
Tuesday, May 16, 2023
Princess, Electricity, Interim, The Company, PPR, MD, Bank statement, SEDAR, Airline

CALGARY, Alberta, May 15, 2023 (GLOBE NEWSWIRE) -- Prairie Provident Resources Inc. ("Prairie Provident", "PPR" or the "Company") announces our operating and financial results for the first quarter ended March 31, 2023.

Key Points: 
  • CALGARY, Alberta, May 15, 2023 (GLOBE NEWSWIRE) -- Prairie Provident Resources Inc. ("Prairie Provident", "PPR" or the "Company") announces our operating and financial results for the first quarter ended March 31, 2023.
  • Patrick McDonald, Interim President and CEO commented: “The operations team has done an excellent job of maintaining production levels through the first quarter of 2023 while deploying minimal capital.
  • First quarter 2023 operating netback1 before the impact of derivatives was $4.5 million ($13.46/boe), and $3.9 million ($11.69/boe) after realized losses on derivatives, a $2.0 million and $1.7 million decrease from the fourth quarter of 2022, respectively.
  • Operating expenses for the first quarter of 2023 decreased by $0.92 per boe of production from the fourth quarter of 2022 principally due to capital discipline.

Master Athletics Partners with the Professional Pickleball Registry

Retrieved on: 
Friday, May 5, 2023
Master, DNA, Para-athletics, Partnership, PTR, PPR, Education, USAPA, USA Pickleball, Sports equipment

YORKTOWN HEIGHTS, N.Y., May 5, 2023 /PRNewswire-PRWeb/ -- Master Athletics, a leading manufacturer of pickleball and platform tennis paddles, balls and accessories, has announced an official corporate partnership with the Professional Pickleball Registry (PPR).

Key Points: 
  • YORKTOWN HEIGHTS, N.Y., May 5, 2023 /PRNewswire-PRWeb/ -- Master Athletics , a leading manufacturer of pickleball and platform tennis paddles, balls and accessories, has announced an official corporate partnership with the Professional Pickleball Registry (PPR).
  • "Being at the grassroots of pickleball is in our DNA, so to partner with the PPR is incredibly exciting for everyone at Master.
  • PPR is the official education and certification partner of the USA Pickleball Association (USAPA).
  • PPR is a subsidiary of the Professional Tennis Registry (PTR) and combines PTR's 40+ years of expertise in the racquets industry with the expertise of 5-time National Pickleball Champion, Sarah Ansboury, to develop courses and workshop materials to certify PPR members to teach pickleball.

Anderson-Negele's Paperless Process Recorder Receives FDA Memorandum-b

Retrieved on: 
Monday, May 1, 2023
Engineering, Health, FDA, Technology, Manufacturing, Software, Hardware, Product management, Food, PPR, Risk, Pasteurization, PMO, Letter, Medical device

Anderson-Negele, a leading manufacturer of instrumentation for the food and beverage industry, is excited to announce that the FDA has issued its Paperless Process Recorder (PPR) a Memorandum-b.

Key Points: 
  • Anderson-Negele, a leading manufacturer of instrumentation for the food and beverage industry, is excited to announce that the FDA has issued its Paperless Process Recorder (PPR) a Memorandum-b.
  • The FDA has never issued a Memorandum-b for an electronic recorder/controller to be used in pasteurization applications.
  • With the M-b-383, Anderson-Negele's PPR is now the first and currently only digital recorder and controller to achieve this.
  • The Paperless Process Recorder, with its advanced Legendary™ Software, provides food and beverage plants with a next-generation solution for process monitoring and control.

Prairie Provident Resources Announces Fourth Quarter and Year-End 2022 Financial and Operating Results and Update on Repositioning Plan

Retrieved on: 
Saturday, April 1, 2023
PPR, Bank statement, Lien, Recapitalization, Equity (finance), G&A, Equity, US, Subordination, The Company, Finance Secretary (India), Outline, MD, SEDAR, Mortgage law, Growth, Completion, Cryptocurrency, Security (finance)

CALGARY, Alberta, April 01, 2023 (GLOBE NEWSWIRE) -- Prairie Provident Resources Inc. ("Prairie Provident", "PPR" or the "Company") announces our operating and financial results for the fourth quarter and year ended 2022.

Key Points: 
  • CALGARY, Alberta, April 01, 2023 (GLOBE NEWSWIRE) -- Prairie Provident Resources Inc. ("Prairie Provident", "PPR" or the "Company") announces our operating and financial results for the fourth quarter and year ended 2022.
  • Although the Company achieved production only slightly (6%) below previously guided volumes, 2022 saw headwinds for Prairie Provident, primarily through $25.5 million of realized hedging losses from mandatory credit facility hedging requirements.
  • Earlier this week PPR announced a comprehensive recapitalization plan to significantly improve the Company's financial flexibility and sustainability (detailed below).
  • From an improved financial position from the recapitalization explore transactions that may unlock value within the Company.

Prairie Provident Resources Announces Closing of $5 Million Second Lien Financing

Retrieved on: 
Friday, March 31, 2023
NEWS, Mortgage law, TSX, NOT, WIRE, FOR, PPR, PCEP, Cryptocurrency

CALGARY, Alberta, March 31, 2023 (GLOBE NEWSWIRE) -- Prairie Provident Resources Inc. (TSX: PPR) ("Prairie Provident" or the "Company") is pleased to announce that it has completed the issuance of second lien notes due December 31, 2024 in the principal amount of US$3.64 million (equivalent to approximately C$5 million) (the “Second Lien Notes”) with certain affiliates of PCEP Canadian Holdco, LLC (the “PCEP”) (the “Second Lien Financing”). The Second Lien Financing is being completed in connection with the recently announced recapitalization transactions (collectively, the “Recapitalization”). PCEP is controlled by the investment management arm of one of the world’s largest financial institutions, which has over US$1 trillion in assets under management.

Key Points: 
  • NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE U.S.
    CALGARY, Alberta, March 31, 2023 (GLOBE NEWSWIRE) -- Prairie Provident Resources Inc. (TSX: PPR) ("Prairie Provident" or the "Company") is pleased to announce that it has completed the issuance of second lien notes due December 31, 2024 in the principal amount of US$3.64 million (equivalent to approximately C$5 million) (the “Second Lien Notes”) with certain affiliates of PCEP Canadian Holdco, LLC (the “PCEP”) (the “Second Lien Financing”).
  • The Second Lien Financing is being completed in connection with the recently announced recapitalization transactions (collectively, the “Recapitalization”).
  • PCEP is controlled by the investment management arm of one of the world’s largest financial institutions, which has over US$1 trillion in assets under management.
  • Patrick McDonald, Chairman of the Company, stated: “PPR is pleased that PCEP has demonstrated strong support for the Company and the Recapitalization with this investment of $5 million of new funds.

Prairie Provident Resources Announces Transformative Recapitalization Transactions

Retrieved on: 
Wednesday, March 29, 2023
Unit, Person, Fund for Protection of Investors' Rights in Foreign States, Lung compliance, Equity, Agent, Security (finance), Acquisition, Repayment plan, Toronto Stock Exchange, News, PPR, Recapitalization, Commodity, Amendment, National instrument, Debt, Mortgage law, TSX, Growth, Common, Exercise, Adjustment, CAD, Regulation, Acceleration, Indian stock exchange, SOFR, Equity (finance), Sale, Prospectus, Bank, PCEP, Rare-earth element, Commercial property, Cryptocurrency, Holding company, USD, Subordination, Warrant, Holder in due course

Going forward, completion of the Recapitalization is expected to provide Prairie Provident with a sustainable capital structure and the capital resources necessary to optimize its current producing assets as well as develop its currently undeveloped land base, for the benefit of all stakeholders.

Key Points: 
  • Going forward, completion of the Recapitalization is expected to provide Prairie Provident with a sustainable capital structure and the capital resources necessary to optimize its current producing assets as well as develop its currently undeveloped land base, for the benefit of all stakeholders.
  • In recent years, Prairie Provident has faced an increasingly challenging lack of liquidity and deteriorating capital resource position.
  • Prairie Provident intends to close the Equity Financing as soon as possible in order to address its near-term working capital needs.
  • As the Noteholder will, after giving effect to the Subordinated Notes Conversion, Warrant Exercise and Equity Financing, hold more than 80% of the outstanding Common Shares after the Recapitalization, the Noteholder will be a 'control person' of Prairie Provident under applicable Canadian securities laws, and the Recapitalization will materially affect control of Prairie Provident within the meaning of TSX rules.

KULR Reports Record Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
Thursday, March 23, 2023
Lithium, Database, CES, Advertising, JSC, Lockheed Martin, EV, PPR, SG, Education, Marketing, Safety, ISC, JPL (Integrated Communications, Inc.), Intelligence, Lockheed, Recycling, Satellite, KULR, NASA, Customer, Administration, SAN, Algorithm, CFO, Growth, Gamma, Transport, NYSE, Automation, Video game, Renewable energy, Cryptocurrency, Electric battery, Communications satellite, Pharmaceutical industry, Fine chemical, Artemis

SAN DIEGO, March 23, 2023 (GLOBE NEWSWIRE) -- KULR Technology Group, Inc. (NYSE American: KULR) (the "Company" or "KULR"), a leading energy management platform company accelerating the global transition to a sustainable electrification economy, today announced its financial results for the fourth quarter and full-year 2022.

Key Points: 
  • SAN DIEGO, March 23, 2023 (GLOBE NEWSWIRE) -- KULR Technology Group, Inc. (NYSE American: KULR) (the "Company" or "KULR"), a leading energy management platform company accelerating the global transition to a sustainable electrification economy, today announced its financial results for the fourth quarter and full-year 2022.
  • R&D expenses: R&D expenses in the fourth quarter of 2022 increased to $1,187,000 from $705,000 in the same period last year.
  • Operating Loss: Loss from operations was $3,987,000 for the fourth quarter of 2022, compared to $4,013,000 from the same period last year.
  • Higher SG&A costs offset higher sales while the gross margin increased from 70% in the fourth quarter of 2021 to 92% in the comparable 2022 quarter.

Journey Medical Corporation Announces Completion of Treatment Assessing Impact of DFD-29 (Minocycline Modified Release Capsules 40 mg) on Microbial Flora in a Separate Phase 1 Clinical Trial

Retrieved on: 
Thursday, March 16, 2023
Forehead, PPR, Doxycycline, Minocycline, Skin, Patient, Microbiology, Vagina, Safety, Clinical trial, NDA, Marketing, Entrepreneurship, Pharmaceutical industry, Dietary supplement, Rosacea

SCOTTSDALE, Ariz., March 16, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage biopharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, today announced completion of treatment in the Phase 1 clinical trial assessing the impact of DFD-29 (Minocycline Modified Release Capsules 40 mg) on the microbial flora of healthy adults. The clinical trial is also assessing the safety and tolerability of the treatment. DFD-29 is being developed for the treatment of papulopustular rosacea (“PPR”) in collaboration with Dr. Reddy’s Laboratories Ltd.

Key Points: 
  • The clinical trial is also assessing the safety and tolerability of the treatment.
  • Additional information on the DFD-29 Phase 1 clinical trial can be found on ClinicalTrials.gov using the identifier: NCT05597462 .
  • In addition, we are pleased that the DFD-29 Phase 3 clinical trials have been fully enrolled as of January 2023.
  • The secondary objective is to evaluate the safety, efficacy and tolerability of DFD-29 compared to Oracea® (Doxycycline capsules 40 mg).